{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05537766",
            "orgStudyIdInfo": {
                "id": "KT-US-568-0138"
            },
            "secondaryIdInfos": [
                {
                    "id": "2022-501259-10",
                    "type": "OTHER",
                    "domain": "European Medicines Agency"
                },
                {
                    "id": "2022-501260-18",
                    "type": "OTHER",
                    "domain": "European Medicines Agency"
                },
                {
                    "id": "2022-501261-46",
                    "type": "OTHER",
                    "domain": "European Medicines Agency"
                },
                {
                    "id": "2022-501262-21",
                    "type": "OTHER",
                    "domain": "European Medicines Agency"
                }
            ],
            "organization": {
                "fullName": "Gilead Sciences",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies",
            "officialTitle": "A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25)",
            "acronym": "ZUMA-25",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "study-of-brexucabtagene-autoleucel-in-adults-with-rare-b-cell-malignancies"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-11-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-03",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-03",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-09-08",
            "studyFirstSubmitQcDate": "2022-09-08",
            "studyFirstPostDateStruct": {
                "date": "2022-09-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-03",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-06",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Kite, A Gilead Company",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Master protocol: The goal of this master clinical study is to test how well the study drug, brexucabtagene autoleucel, works in participants with rare B-cell malignancies: relapsed/refractory Waldenstrom macroglobulinemia (r/r WM) (Substudy A - no longer recruiting), relapsed/refractory Richter transformation (r/r RT) (Substudy B), relapsed/refractory Burkitt lymphoma (r/r BL) (Substudy C and relapsed/refractory hairy cell leukemia (r/r HCL) (Substudy D - no longer recruiting).",
            "detailedDescription": "Master protocol: The primary objective of this study is to evaluate the efficacy of brexucabtagene autoleucel in two rare B-cell malignancies. This study will use a basket study design with separate, indication-specific substudies, to investigate r/r RT and r/r BL.\n\nAfter completing the treatment period, all participants will be followed in the post-treatment follow-up period. Thereafter, participants will transition to a separate long-term follow-up study (KT-US-982-5968) to continue follow-up out to 15 years.\n\nSubstudies A and D have been early terminated by the sponsor."
        },
        "conditionsModule": {
            "conditions": [
                "Relapsed/Refractory Waldenstrom Macroglobulinemia",
                "Relapsed/Refractory Richter Transformation",
                "Relapsed/Refractory Burkitt Lymphoma",
                "Relapsed/Refractory Hairy Cell Leukemia"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 90,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Substudy A (Relapsed/Refractory Waldenstrom Macroglobulinemia): Brexucabtagene Autoleucel",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day lymphodepletion chemotherapy for 3 days followed by a single infusion of brexucabtagene autoleucel at target dose of 2 \u00d7 10\\^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg.\n\nThis arm is no longer recruiting.",
                    "interventionNames": [
                        "Biological: Brexucabtagene Autoleucel",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine"
                    ]
                },
                {
                    "label": "Substudy B (Relapsed/Refractory Richter Transformation): Brexucabtagene Autoleucel",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day lymphodepletion chemotherapy for 3 days followed by a single infusion of brexucabtagene autoleucel at target dose of 2\u00d710\\^6 anti-CD19 CAR T cells/kg.\n\nThis arm is no longer recruiting.",
                    "interventionNames": [
                        "Biological: Brexucabtagene Autoleucel",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine"
                    ]
                },
                {
                    "label": "Substudy C (Relapsed/Refractory Burkitt Lymphoma): Brexucabtagene Autoleucel",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day lymphodepletion chemotherapy for 3 days followed by a single infusion of brexucabtagene autoleucel at a target dose of 2x10\\^6 anti-CD19 CAR T cells/kg.",
                    "interventionNames": [
                        "Biological: Brexucabtagene Autoleucel",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine"
                    ]
                },
                {
                    "label": "Substudy D (Relapsed/Refractory hairy cell leukemia): Brexucabtagene Autoleucel",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day lymphodepletion chemotherapy for 3 days followed by a single infusion of brexucabtagene autoleucel at a target dose of 2 \u00d7 10\\^6 anti-CD19 CAR T cells/kg.\n\nThis arm is no longer recruiting.",
                    "interventionNames": [
                        "Biological: Brexucabtagene Autoleucel",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "Brexucabtagene Autoleucel",
                    "description": "Administered intravenously",
                    "armGroupLabels": [
                        "Substudy A (Relapsed/Refractory Waldenstrom Macroglobulinemia): Brexucabtagene Autoleucel",
                        "Substudy B (Relapsed/Refractory Richter Transformation): Brexucabtagene Autoleucel",
                        "Substudy C (Relapsed/Refractory Burkitt Lymphoma): Brexucabtagene Autoleucel",
                        "Substudy D (Relapsed/Refractory hairy cell leukemia): Brexucabtagene Autoleucel"
                    ],
                    "otherNames": [
                        "KTE-X19"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide",
                    "description": "Administered intravenously",
                    "armGroupLabels": [
                        "Substudy A (Relapsed/Refractory Waldenstrom Macroglobulinemia): Brexucabtagene Autoleucel",
                        "Substudy B (Relapsed/Refractory Richter Transformation): Brexucabtagene Autoleucel",
                        "Substudy C (Relapsed/Refractory Burkitt Lymphoma): Brexucabtagene Autoleucel",
                        "Substudy D (Relapsed/Refractory hairy cell leukemia): Brexucabtagene Autoleucel"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fludarabine",
                    "description": "Administered intravenously",
                    "armGroupLabels": [
                        "Substudy A (Relapsed/Refractory Waldenstrom Macroglobulinemia): Brexucabtagene Autoleucel",
                        "Substudy B (Relapsed/Refractory Richter Transformation): Brexucabtagene Autoleucel",
                        "Substudy C (Relapsed/Refractory Burkitt Lymphoma): Brexucabtagene Autoleucel",
                        "Substudy D (Relapsed/Refractory hairy cell leukemia): Brexucabtagene Autoleucel"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Substudy A: Combined Rate of Complete Response (CR) and Very Good Partial Response (VGPR) Determined by Central Assessment per the Sixth International Workshop in Waldenstrom Macroglobulinemia (WM)",
                    "description": "Combined rate is defined as the proportion of participants who achieve either CR or VGPR.",
                    "timeFrame": "Up to 5 years"
                },
                {
                    "measure": "Substudy B: Objective Response Rate (ORR) Determined by Central Assessment per the Lugano Classification",
                    "description": "ORR is defined as the proportion of participants who achieve a best response of either CR or partial response (PR).",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Substudy C: ORR Determined by Central Assessment per the Lugano Classification",
                    "description": "ORR is defined as the proportion of participants who achieve a best response of either CR or PR.",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Substudy D: ORR Determined by Central Assessment per the Response Criteria Described by Grever and Colleagues",
                    "description": "ORR is defined as the proportion of participants who achieve either CR or PR.",
                    "timeFrame": "Up to 5 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "All Substudies (Substudies A, B, C and D): Complete Response (CR) Rate Determined by Central Assessment",
                    "description": "CR rate is defined as proportion of participants who achieve CR.",
                    "timeFrame": "Up to 2 years for substudies B and C; Up to 5 years for substudies A and D"
                },
                {
                    "measure": "All Substudies (Substudies A, B, C and D): Duration of Response (DOR)",
                    "description": "DOR is defined as time from first objective response to disease progression per indication specific response criteria or death from any cause.",
                    "timeFrame": "Up to 2 years for substudies B and C; Up to 5 years for substudies A and D"
                },
                {
                    "measure": "All Substudies (Substudies A, B, C and D): Overall Survival (OS)",
                    "description": "OS is defined as the time from enrollment or brexucabtagene autoleucel infusion to death from any cause.",
                    "timeFrame": "Up to 2 years for substudies B and C; Up to 5 years for substudies A and D"
                },
                {
                    "measure": "All Substudies (Substudies A, B, C and D): Progression Free Survival (PFS)",
                    "description": "PFS is defined as the time from enrollment or brexucabtagene autoleucel infusion to disease progression per indication specific response criteria or death from any cause.",
                    "timeFrame": "Up to 2 years for substudies B and C; Up to 5 years for substudies A and D"
                },
                {
                    "measure": "All Substudies (Substudies A, B, C and D): Time to Next Treatment (TTNT)",
                    "description": "TTNT defined as the time from enrollment or brexucabtagene autoleucel infusion to the initiation of subsequent anticancer treatment.",
                    "timeFrame": "Up to 2 years for substudies B and C; Up to 5 years for substudies A and D"
                },
                {
                    "measure": "All Substudies (Substudies A, B, C and D): Time to First Response",
                    "description": "Time to first response is defined as the time from enrollment or brexucabtagene autoleucel infusion to first objective response.",
                    "timeFrame": "Up to 2 years for substudies B and C; Up to 5 years for substudies A and D"
                },
                {
                    "measure": "All Substudies (Substudies A, B, C and D): Time to Best Response",
                    "description": "Time to best response is defined as the time from enrollment or brexucabtagene autoleucel infusion to best objective response.",
                    "timeFrame": "Up to 2 years for substudies B and C; Up to 5 years for substudies A and D"
                },
                {
                    "measure": "All Substudies (Substudies A, B, C and D): Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)",
                    "timeFrame": "First infusion date up to 2 years plus 30 days for substudies B and C; First infusion date up to 5 years plus 30 days for substudies A and D"
                },
                {
                    "measure": "All Substudies (Substudies A, B, C and D): Percentage of Participants Experiencing Clinically Significant Changes in Safety Laboratory Values",
                    "timeFrame": "First infusion date up to 2 years plus 30 days for substudies B and C; First infusion date up to 5 years plus 30 days for substudies A and D"
                },
                {
                    "measure": "All Substudies (Substudies A, B, C and D): Percentage of Participants Experiencing Adverse Events (AEs) Defined as Dose Limiting Toxicities (DLTs)",
                    "description": "Dose-limiting toxicity is defined as protocol-defined brexucabtagene autoleucel-related events with onset within the first 28 days following brexucabtagene autoleucel infusion.",
                    "timeFrame": "First infusion date of brexucabtagene autoleucel up to 28 days"
                },
                {
                    "measure": "All Substudies (Substudies A, B, C and D): Percentage of Participants With Positive Anti-brexucabtagene autoleucel Antibodies",
                    "timeFrame": "First infusion date Up to 2 years for substudies B and C; First infusion date Up to 5 years for substudies A and D"
                },
                {
                    "measure": "All Substudies (Substudies A, B, C and D): Percentage of Participants With Replication-competent Retrovirus (RCR) in Peripheral Blood Mononuclear Cells (PBMCs)",
                    "timeFrame": "Baseline, Month 12"
                },
                {
                    "measure": "All Substudies (Substudies A, B, C and D): Change From Baseline in the European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire-30 (EORTC QLQ-C30) Score",
                    "description": "The EORTC-QLQ-C30 is a multi-item questionnaire measuring the following content five (5) multi-item functional scales, six (6) multi-item symptom scales, one (1) global health status scale, and one (1) global health-related quality of life (HRQoL) each scale is measured from 0 to 100 after a linear transformation. Higher scores for functioning scales and for the Global Health Status or Global HRQoL scales indicate a higher level of functioning and a better HRQoL respectively, whereas higher scores in symptom scales represent a higher level of symptoms.",
                    "timeFrame": "Baseline, up to 24 months"
                },
                {
                    "measure": "All Substudies (Substudies A, B, C and D): Changes From Baseline in the European Quality of Life Five Dimensions Five Levels Questionnaire (EQ-5D-5L) Score",
                    "description": "The EQ-5D-5L questionnaire is a generic measure of health status that provides a simple descriptive profile and a single index value. The EQ-5D-5L comprises 2 components: a questionnaire covering 5 dimensions and a tariff of values based upon direct valuations of health states using a visual analog scale (VAS). Rating gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health.",
                    "timeFrame": "Baseline, Up to 24 months"
                },
                {
                    "measure": "Substudy A: ORR Determined by Central Assessment",
                    "description": "ORR is defined as the proportion of participants who achieve a best response of CR, VGPR, or PR.",
                    "timeFrame": "Up to 5 years"
                },
                {
                    "measure": "Substudy A: Combined CR and VGPR Rate Determined by Investigator Assessment",
                    "description": "Combined rate is defined as the proportion of participants who achieve either CR or VGPR.",
                    "timeFrame": "Up to 5 years"
                },
                {
                    "measure": "Substudy A: PR Rate Determined by Central Assessment",
                    "description": "PR rate is defined as proportion of participants who achieve PR.",
                    "timeFrame": "Up to 5 years"
                },
                {
                    "measure": "Substudy A: VGPR Rate Determined by Central Assessment",
                    "description": "VGPR rate is defined as proportion of participants who achieve VGPR.",
                    "timeFrame": "Up to 5 years"
                },
                {
                    "measure": "Substudy B: ORR Determined by Investigator Assessment per the Lugano Classification",
                    "description": "ORR is defined as the proportion of participants who achieve a best response of either CR or PR.",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Substudy B: ORR Determined by Central Assessment per the Lugano Classification",
                    "description": "ORR is defined as the proportion of participants who achieve a best response of either CR or PR, in subgroups by clonal relationship to the underlying CLL. Clonality will be assessed by central assessment.",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Substudy B: ORR Determined by Investigator per International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2018 Criteria",
                    "description": "ORR is defined as the proportion of participants who achieve a best response of either CR, complete response with incomplete marrow recovery (CRi) or PR.",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Substudy C: ORR Determined by Investigator Assessment per the Lugano Classification",
                    "description": "ORR is defined as the proportion of participants who achieve a best response of either CR or PR.",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Substudy D: ORR Determined by Investigator Assessment",
                    "description": "ORR is defined as the proportion of participants who achieve either CR or PR.",
                    "timeFrame": "Up to 5 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\nAll Substudies:\n\n* Presence of toxicities due to prior therapy must be stable and recovered to Grade 1 or lower.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n* Adequate hematologic and end-organ function.\n* Individuals of childbearing potential who engage in heterosexual intercourse must agree to use specified method(s) of contraception.\n\nSubstudy B:\n\n* Confirmed diagnosis of chronic lymphocytic leukemia (CLL) based on International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2018 criteria with histologically confirmed Richter transformation (RT) to a diffuse large B-cell lymphoma (DLBCL) subtype.\n* Relapsed or refractory disease after 1 line of therapy, defined as at least 1 of the following:\n\n  * Refractory disease, defined as progressive disease or stable disease as best response to first-line therapy.\n  * Relapsed disease, defined as complete remission to first-line therapy followed by biopsy-proven disease relapse.\n* At least 1 measurable lesion based on the Lugano Classification. Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy.\n\nSubstudy C:\n\n* Histologically confirmed mature B-cell non-Hodgkin lymphoma (NHL) Burkitt lymphoma/leukemia.\n* Relapsed or refractory disease after first-line chemoimmunotherapy, defined as 1 of the following:\n\n  * Refractory disease, defined as progressive disease or stable disease as best response to first-line therapy; individuals who are intolerant to first-line therapy are excluded.\n  * Relapsed disease, defined as complete remission to first-line therapy followed by biopsy-proven disease relapse.\n* At least 1 measurable lesion based on the Lugano Classification. Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy.\n\nKey Exclusion Criteria:\n\nAll Substudies:\n\n* Prior CAR therapy or treatment with any anti-CD19 therapy.\n* HIV-positive patients, unless taking appropriate anti-HIV medications, having an undetectable viral load by quantitative polymerase chain reaction (qPCR) and a CD4 count \\> 200 cells/uL.\n* Presence of detectable cerebrospinal fluid malignant cells or brain metastases.\n* History of autoimmune disease (eg, Crohn's disease, rheumatoid arthritis, systemic lupus).\n\nSubstudy B:\n\n* Diagnosis of RT not of DLBCL subtype (including, but not limited to, Hodgkin lymphoma (HL) and prolymphocytic leukemia).\n* Prior allogeneic or autologous stem cell transplant \\< 3 months prior to screening and/or \\< 4 months prior to planned infusion of brexucabtagene autoleucel.\n* Presence of active graft-versus-host disease following prior stem cell transplant.\n\nSubstudy C:\n\n* Burkitt-like lymphoma with 11q aberration, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement, or high-grade B-cell lymphoma not otherwise specified.\n* Prior allogeneic stem cell transplant \\< 3 months prior to screening and/or \\< 4 months prior to planned infusion of brexucabtagene autoleucel.\n* Presence of active graft-versus-host disease following prior allogeneic stem cell transplant.\n* Presence of CNS involvement. Individuals with a prior history of CNS involvement are eligible if they show a negative CSF and no involvement by imaging.\n\nSubstudies A and D have been early terminated by the sponsor.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Medical Information",
                    "role": "CONTACT",
                    "phone": "844-454-5483(1-844-454-KITE)",
                    "email": "medinfo@kitepharma.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Kite Study Director",
                    "affiliation": "Kite, A Gilead Company",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "City of Hope (City of Hope National Medical Center)",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "Stanford Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Stanford",
                    "state": "California",
                    "zip": "94305",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.42411,
                        "lon": -122.16608
                    }
                },
                {
                    "facility": "Colorado Blood Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80218",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "Georgetown University Medical Centre",
                    "status": "RECRUITING",
                    "city": "Washington",
                    "state": "District of Columbia",
                    "zip": "20037",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.89511,
                        "lon": -77.03637
                    }
                },
                {
                    "facility": "University of Iowa",
                    "status": "RECRUITING",
                    "city": "Iowa City",
                    "state": "Iowa",
                    "zip": "52242",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.66113,
                        "lon": -91.53017
                    }
                },
                {
                    "facility": "Dana Farber Cancer Institute",
                    "status": "WITHDRAWN",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Washington University School of Medicine",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Hackensack University Medical Center",
                    "status": "RECRUITING",
                    "city": "Hackensack",
                    "state": "New Jersey",
                    "zip": "07601",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.88593,
                        "lon": -74.04347
                    }
                },
                {
                    "facility": "The Ohio State University Wexner Medical Center - James Cancer HospitalS",
                    "status": "RECRUITING",
                    "city": "Columbus",
                    "state": "Ohio",
                    "zip": "43210",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.96118,
                        "lon": -82.99879
                    }
                },
                {
                    "facility": "UPMC Hillman Cancer Center",
                    "status": "RECRUITING",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15232",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                },
                {
                    "facility": "Tennessee Oncology, PLLC",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Vanderbilt University",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37232",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Medical University of Vienna, Department of Internal Medicine I, Div. of Hematology",
                    "status": "RECRUITING",
                    "city": "Vienna",
                    "zip": "01090",
                    "country": "Austria",
                    "geoPoint": {
                        "lat": 48.20849,
                        "lon": 16.37208
                    }
                },
                {
                    "facility": "Hopital de la Pitie Salpetriere",
                    "status": "RECRUITING",
                    "city": "Paris",
                    "zip": "75013",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.85341,
                        "lon": 2.3488
                    }
                },
                {
                    "facility": "Centre hospitalier de Toulouse - Hematology department",
                    "status": "RECRUITING",
                    "city": "Toulouse Cedex 09",
                    "zip": "31059",
                    "country": "France",
                    "geoPoint": {
                        "lat": 43.60426,
                        "lon": 1.44367
                    }
                },
                {
                    "facility": "Universitatsklinikum Heidelberg",
                    "status": "RECRUITING",
                    "city": "Heidelberg",
                    "zip": "69120",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 49.40768,
                        "lon": 8.69079
                    }
                },
                {
                    "facility": "Universitatsklinikum Koln",
                    "status": "RECRUITING",
                    "city": "Koln",
                    "zip": "50937",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 50.93333,
                        "lon": 6.95
                    }
                },
                {
                    "facility": "Universitatsklinikum Ulm",
                    "status": "RECRUITING",
                    "city": "Ulm",
                    "zip": "89081",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 48.39841,
                        "lon": 9.99155
                    }
                },
                {
                    "facility": "IRCCS Azienda Ospedaliero - Universitaria di Bologna",
                    "status": "RECRUITING",
                    "city": "Bologna",
                    "zip": "40138",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 44.49381,
                        "lon": 11.33875
                    }
                },
                {
                    "facility": "ASST Grande Ospedale Metropolitano Niguarda",
                    "status": "RECRUITING",
                    "city": "Milano",
                    "zip": "20162",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.46427,
                        "lon": 9.18951
                    }
                },
                {
                    "facility": "Azienda Ospedale di Perugia - Ospedale S. Maria della Misericordia",
                    "status": "RECRUITING",
                    "city": "Perugia",
                    "zip": "06132",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 43.1122,
                        "lon": 12.38878
                    }
                },
                {
                    "facility": "Radboud University Nijmegen Medical Centre",
                    "status": "RECRUITING",
                    "city": "Nijmegen",
                    "zip": "6525 GA",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 51.8425,
                        "lon": 5.85278
                    }
                },
                {
                    "facility": "Hospital Clinic de Barcelona",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08036",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hospital Universitario de Salamanca",
                    "status": "RECRUITING",
                    "city": "Salamanca",
                    "zip": "37007",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.96882,
                        "lon": -5.66388
                    }
                },
                {
                    "facility": "Hospital Universitario Virgen del Rocio",
                    "status": "RECRUITING",
                    "city": "Sevilla",
                    "zip": "41013",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 37.38283,
                        "lon": -5.97317
                    }
                },
                {
                    "facility": "Istituto Oncologico Della Svizzera Italiana (IOSI)",
                    "status": "RECRUITING",
                    "city": "Bellinzona",
                    "zip": "6500",
                    "country": "Switzerland",
                    "geoPoint": {
                        "lat": 46.19278,
                        "lon": 9.01703
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Gilead Clinical Trials Website",
                    "url": "https://www.gileadclinicaltrials.com/study/?id=KT-US-568-0138"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002051",
                    "term": "Burkitt Lymphoma"
                },
                {
                    "id": "D000008258",
                    "term": "Waldenstrom Macroglobulinemia"
                },
                {
                    "id": "D000007943",
                    "term": "Leukemia, Hairy Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000020031",
                    "term": "Epstein-Barr Virus Infections"
                },
                {
                    "id": "D000006566",
                    "term": "Herpesviridae Infections"
                },
                {
                    "id": "D000004266",
                    "term": "DNA Virus Infections"
                },
                {
                    "id": "D000014777",
                    "term": "Virus Diseases"
                },
                {
                    "id": "D000007239",
                    "term": "Infections"
                },
                {
                    "id": "D000014412",
                    "term": "Tumor Virus Infections"
                },
                {
                    "id": "D000016393",
                    "term": "Lymphoma, B-Cell"
                },
                {
                    "id": "D000008228",
                    "term": "Lymphoma, Non-Hodgkin"
                },
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000054219",
                    "term": "Neoplasms, Plasma Cell"
                },
                {
                    "id": "D000020141",
                    "term": "Hemostatic Disorders"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000010265",
                    "term": "Paraproteinemias"
                },
                {
                    "id": "D000001796",
                    "term": "Blood Protein Disorders"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000006474",
                    "term": "Hemorrhagic Disorders"
                },
                {
                    "id": "D000007938",
                    "term": "Leukemia"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "relevance": "LOW"
                },
                {
                    "id": "M11251",
                    "name": "Waldenstrom Macroglobulinemia",
                    "asFound": "Waldenstrom Macroglobulinemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5321",
                    "name": "Burkitt Lymphoma",
                    "asFound": "Burkitt lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10950",
                    "name": "Leukemia, Hairy Cell",
                    "asFound": "Hairy cell leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M21881",
                    "name": "Epstein-Barr Virus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M9643",
                    "name": "Herpesviridae Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M7442",
                    "name": "DNA Virus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M17162",
                    "name": "Tumor Virus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M18828",
                    "name": "Lymphoma, B-Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M11222",
                    "name": "Lymphoma, Non-Hodgkin",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27588",
                    "name": "Neoplasms, Plasma Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M21977",
                    "name": "Hemostatic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5059",
                    "name": "Blood Coagulation Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13178",
                    "name": "Paraproteinemias",
                    "relevance": "LOW"
                },
                {
                    "id": "M5077",
                    "name": "Blood Protein Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9560",
                    "name": "Hemorrhagic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T5018",
                    "name": "Richter Syndrome",
                    "asFound": "Richter's Transformation",
                    "relevance": "HIGH"
                },
                {
                    "id": "T5887",
                    "name": "Waldenstrom Macroglobulinemia",
                    "asFound": "Waldenstrom Macroglobulinemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T892",
                    "name": "Burkitt Lymphoma",
                    "asFound": "Burkitt lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2650",
                    "name": "Hairy Cell Leukemia",
                    "asFound": "Hairy cell leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T640",
                    "name": "B-cell Lymphoma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                },
                {
                    "id": "C000705347",
                    "term": "Brexucabtagene autoleucel"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M163173",
                    "name": "Brexucabtagene autoleucel",
                    "asFound": "Dichloroacetate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}